Uncategorized

Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price – Investor’s Business Daily

Posted on Author Tim Hodges Comments Off on Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price – Investor’s Business Daily
  1. Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price  Investor’s Business Daily
  2. Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs  The New York Times
  3. Novo Nordisk: CEO’s Surprise Departure Points to Challenging Obesity Market Dynamics  Morningstar
  4. Novo Nordisk ousts CEO as Wegovy maker faces growing competition  CNBC
  5. Novo Nordisk rode Ozempic’s success to becoming Europe’s top company. Now it’s faltering and its CEO is out.  MarketWatch